Lurasidone

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C28H36N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22IC88528T, chemically known as (3ar,4s,7r,7as)-2-((1r,2r)-2-(4-(1,2-benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione but generally known as lurasidone, which bears US NIH Compound Identifier 213046. European Medicines Agency schedules Lurasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32185. The term LURASIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). Most nations schedule lurasidone under HS 29341000 and SITC 51579. As of Q4 2014, LURASIDONE remains the US FDA Preferred Term for this commodity. Lurasidone bears US NLM identifiers UMLS ID C2003424 and NCI Concept Code C77575. SMILES: S1NC(N2CCN(CC3C(CN4C(=O)C5C6CC(C5C4=O)CC6)CCCC3)CC2)C2C1CCCC2.